礼来Retatrutide在里程碑式试验中表现优于Ozempic；美联储维持利率稳定
· thestockmarketwatch.com
Eli Lilly（LLY）今日宣布，其下一代肥胖治疗药物retatrutide在一项里程碑式试验中显著优于诺和诺德（NVO）的Ozempic。
This update was written automatically with AI from market data and news wire reports, and published without review by a person.
Key Takeaways
Eli Lilly (LLY) ...